Researchers at Kumamoto University have discovered a monoclonal antibody capable of neutralizing a wide range of SARS-CoV-2 ...

Scientists examine the effectiveness of an antibody targeting cell adhesion molecule 1 in alleviating pain-induced neuronal ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD ...

Beyfortus, a long-acting RSV antibody treatment for infants, will launch in Korea next month, aiming to address rising ...

Kinevant Sciences, a Roivant spinout designed to test an investigational monoclonal antibody, has reported that the asset ...

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Duality Biologics ('DualityBio'), a clinical-stage biotech company focusing on the discovery and development of ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Kumamoto University researchers have identified a powerful antibody that can neutralize a wide range of SARS-CoV-2 variants, ...